Table 3.
Baseline of patients with HCC who met the “Up-to-seven” criteria and had AFP of < 1000 ng/mL.
| Variables | Overall (n = 153) | Group 1* (n =121) | Group 2* (n = 32) | P |
|---|---|---|---|---|
| Demographic data | ||||
| Age (years) | 53.0 (48.0, 58.0) | 54.0 (48.0, 59.0) | 53.0 (48.5, 56.0) | 0.455 |
| Sex Male Female |
136 (88.9%) 17 (11.1%) |
106 (87.6%) 15 (12.4%) |
30 (93.8%) 2 (6.3%) |
0.325 |
| BMI (Kg/m2) | 24.4 (22.7, 27.0) | 24.3 (22.7, 26.7) | 24.8 (22.8, 28.8) | 0.143 |
| Etiology of liver disease CHB CHC Alcoholic Others |
109 (71.2%) 9 (5.9%) 24 (15.7%) 11 (7.2%) |
85 (70.2%) 8 (6.6%) 18 (14.9%) 10 (8.3%) |
24 (75.0%) 1 (3.1%) 6 (18.8%) 1 (3.1%) |
0.620 |
| MELD | 11.0 (8.0, 14.0) | 11.0 (8.0, 14.0) | 12.5 (8.5, 17.0) | 0.242 |
| Tumor characteristics | ||||
| AFP values (ng/ml) < 1000 > 1000 |
146 (95.4%) 7 (4.6%) |
121 (100.0%) 0 (0.0%) |
25 (78.1%) 7 (21.9%) |
<0.001 |
| Tumor number ≦2 ≧3 |
131 (85.6%) 22 (14.4%) |
111 (91.7%) 10 (8.3%) |
20 (62.5%) 12 (37.5%) |
<0.001 |
| Max tumor diameter (cm) | 2.8 (1.5, 4.5) | 2.5 (1.5, 3.5) | 6.0 (4.0, 8.5) | <0.001 |
| Sum of tumor diameter (cm) | 3.0 (1.6, 5.0) | 2.5 (1.5, 3.6) | 8.0 (4.9, 10.2) | <0.001 |
| Pre-LT treatment of HCC | ||||
| Pre-LT RAF | 34 (22.2%) | 29 (24.0%) | 5 (15.6%) | 0.313 |
| Pre-LT TACE | 94 (61.4%) | 74 (61.2%) | 20 (62.5%) | 0.890 |
| Explant pathology | ||||
| Microvascular invasion | 88 (57.5%) | 60 (49.6%) | 28 (87.5%) | <0.001 |
| TNM stage I+ II III +IV |
123 (80.4%) 30 (19.6%) |
107 (88.4%) 14 (11.6%) |
16 (50.0%) 16 (50.0%) |
<0.001 |
*Group 1: met the “Up-to-seven” criteria and had AFP of < 1000 ng/mL. *Group 2: did not meet “Up-to-seven” criteria or had AFP of > 1000 ng/mL. BMI, Body mass index; CHB, chronic hepatitis B; CHC, chronic hepatitis C; LT, liver transplantation; RAF, radiofrequency ablation; TACE, transhepatic arterial chemotherapy embolization; MELD, model for end-stage liver disease; AFP, alpha-fetoprotein.